Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Academic Medical Centers | 6 | 2011 | 309 | 0.750 |
Why?
|
| Quality Assurance, Health Care | 4 | 2009 | 250 | 0.620 |
Why?
|
| Cooperative Behavior | 2 | 2011 | 210 | 0.540 |
Why?
|
| Quality Indicators, Health Care | 2 | 2009 | 333 | 0.490 |
Why?
|
| Leadership | 2 | 2011 | 194 | 0.380 |
Why?
|
| Hospitals, University | 1 | 2011 | 53 | 0.370 |
Why?
|
| Diagnosis-Related Groups | 1 | 2011 | 87 | 0.360 |
Why?
|
| Schools, Medical | 1 | 2011 | 142 | 0.340 |
Why?
|
| Safety Management | 2 | 2010 | 137 | 0.330 |
Why?
|
| Respiration, Artificial | 2 | 2006 | 292 | 0.320 |
Why?
|
| Neurosurgical Procedures | 1 | 2010 | 96 | 0.310 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2010 | 249 | 0.260 |
Why?
|
| Hospital Mortality | 1 | 2010 | 845 | 0.240 |
Why?
|
| Survivors | 1 | 2006 | 150 | 0.240 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 443 | 0.220 |
Why?
|
| United States | 9 | 2011 | 7431 | 0.210 |
Why?
|
| Quality of Health Care | 3 | 2010 | 514 | 0.170 |
Why?
|
| Intensive Care Units | 2 | 2006 | 430 | 0.150 |
Why?
|
| Thermometers | 1 | 1996 | 2 | 0.130 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1996 | 5 | 0.130 |
Why?
|
| Pneumonia, Bacterial | 1 | 1997 | 88 | 0.130 |
Why?
|
| Cross Infection | 1 | 1997 | 152 | 0.120 |
Why?
|
| Ambulatory Care | 2 | 2009 | 305 | 0.110 |
Why?
|
| Humans | 16 | 2011 | 59479 | 0.100 |
Why?
|
| Bronchial Fistula | 1 | 1992 | 5 | 0.100 |
Why?
|
| Fistula | 1 | 1992 | 13 | 0.100 |
Why?
|
| Cellulitis | 1 | 1992 | 22 | 0.100 |
Why?
|
| Pneumococcal Infections | 1 | 1992 | 35 | 0.100 |
Why?
|
| Direct Service Costs | 1 | 2011 | 3 | 0.090 |
Why?
|
| Financing, Government | 1 | 2011 | 30 | 0.090 |
Why?
|
| Skin Diseases | 1 | 1992 | 76 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2011 | 119 | 0.090 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2010 | 25 | 0.080 |
Why?
|
| Medication Errors | 1 | 2010 | 109 | 0.080 |
Why?
|
| Heparin | 1 | 2010 | 111 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 101 | 0.080 |
Why?
|
| Patient Care | 1 | 2009 | 78 | 0.080 |
Why?
|
| Trauma Centers | 1 | 2010 | 114 | 0.080 |
Why?
|
| Risk Adjustment | 1 | 2009 | 93 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2010 | 299 | 0.080 |
Why?
|
| Coronary Artery Bypass | 1 | 2010 | 275 | 0.070 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2010 | 153 | 0.070 |
Why?
|
| Organizational Objectives | 1 | 2007 | 57 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1029 | 0.070 |
Why?
|
| Organizational Innovation | 1 | 2007 | 80 | 0.070 |
Why?
|
| Faculty, Medical | 2 | 2009 | 192 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2010 | 815 | 0.070 |
Why?
|
| General Surgery | 1 | 2009 | 191 | 0.070 |
Why?
|
| Health Services Research | 1 | 2007 | 266 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2010 | 479 | 0.060 |
Why?
|
| Medical Audit | 1 | 2006 | 58 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 2516 | 0.060 |
Why?
|
| Organizational Affiliation | 1 | 2005 | 4 | 0.060 |
Why?
|
| Risk Factors | 2 | 2010 | 4991 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2009 | 683 | 0.060 |
Why?
|
| Benchmarking | 1 | 2005 | 135 | 0.060 |
Why?
|
| Information Dissemination | 1 | 2005 | 111 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 1927 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2006 | 5128 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2009 | 748 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 1021 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 706 | 0.050 |
Why?
|
| Databases as Topic | 2 | 2010 | 52 | 0.040 |
Why?
|
| Aged | 3 | 2006 | 13426 | 0.040 |
Why?
|
| Electric Wiring | 1 | 1997 | 1 | 0.030 |
Why?
|
| Tobramycin | 1 | 1997 | 6 | 0.030 |
Why?
|
| Ampicillin | 1 | 1997 | 12 | 0.030 |
Why?
|
| Penicillins | 1 | 1997 | 29 | 0.030 |
Why?
|
| Gentamicins | 1 | 1997 | 23 | 0.030 |
Why?
|
| Nurseries, Hospital | 1 | 1996 | 2 | 0.030 |
Why?
|
| Equipment Safety | 1 | 1996 | 20 | 0.030 |
Why?
|
| Hepatitis B Core Antigens | 1 | 1996 | 4 | 0.030 |
Why?
|
| Adult | 3 | 2006 | 15704 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 1996 | 8 | 0.030 |
Why?
|
| Burns | 1 | 1996 | 41 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 1996 | 245 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 1996 | 76 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1997 | 299 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 1997 | 1286 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 451 | 0.030 |
Why?
|
| Middle Aged | 2 | 2006 | 16342 | 0.030 |
Why?
|
| Equipment Design | 1 | 1996 | 330 | 0.030 |
Why?
|
| Incidence | 1 | 1996 | 1239 | 0.030 |
Why?
|
| Time Factors | 2 | 1997 | 3619 | 0.030 |
Why?
|
| Lung Abscess | 1 | 1992 | 6 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1997 | 737 | 0.020 |
Why?
|
| Cohort Studies | 1 | 1996 | 2377 | 0.020 |
Why?
|
| Pennsylvania | 1 | 2010 | 62 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2010 | 45 | 0.020 |
Why?
|
| Ohio | 1 | 2009 | 24 | 0.020 |
Why?
|
| HIV Infections | 1 | 1996 | 914 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 141 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2009 | 108 | 0.020 |
Why?
|
| Curriculum | 1 | 2009 | 561 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2009 | 619 | 0.020 |
Why?
|
| Female | 3 | 1997 | 30779 | 0.010 |
Why?
|
| Male | 2 | 1997 | 27794 | 0.010 |
Why?
|
| Fetal Blood | 1 | 1997 | 70 | 0.010 |
Why?
|
| Epidemiologic Factors | 1 | 1996 | 4 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1997 | 115 | 0.010 |
Why?
|
| Culture Media | 1 | 1997 | 77 | 0.010 |
Why?
|
| Carrier State | 1 | 1996 | 17 | 0.010 |
Why?
|
| Hepatitis B | 1 | 1996 | 28 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1996 | 127 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1997 | 473 | 0.010 |
Why?
|
| Temperature | 1 | 1997 | 296 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 805 | 0.010 |
Why?
|
| Massachusetts | 1 | 1996 | 2023 | 0.010 |
Why?
|